The Immediate-Release Patch is the newest version of the Transcatheter Patch, which is a bioabsorbable device for the closure of cardiac defects. Closure of 12 atrial septal defects and 1 fenestration was attempted using this device. Of the 13 devices used, 12 were implanted successfully (including that for the fenestration), whereas 1 device moved from the original position and was retrieved percutaneously. No other major adverse events occurred. After a median follow-up period of 11 months, trivial (≤ 2-mm) residual shunts remained in two patients, and a significant residual defect (7 mm) remained in 1 patient. The major advantages of this device include its wirelessness, its bioabsorbablity, potential application for defects up to 30 mm using only three sizes, its easier retrieval, and its ability to occlude defects with a deficient rim and some ostium primum and sinus venosus type defects. In contrast to the metal devices, it is bulkier and has a different application method requiring operator familiarity, and it sometimes leaves residual shunts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00246-012-0284-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Safe Opioid Prescribing: A Paradigm Shift in Buprenorphine Management for Orthopaedic Surgery.
J Arthroplasty
January 2025
Department of Orthopedics, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
The worsening opioid epidemic in the United States, exacerbated by the COVID-19 pandemic, necessitates innovative approaches to pain management. Buprenorphine, a long-acting opioid, has gained popularity due to its safety profile and accessibility. Orthopaedic surgeons, encountering an increasing number of patients on buprenorphine, face challenges in perioperative management.
View Article and Find Full Text PDFGuidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.
J Neurosci Rural Pract
October 2023
Centre for Brain Research, Indian Institute of Science, Bengaluru, Karnataka, India.
Article Synopsis
- The rise in dementia, particularly Alzheimer’s disease (AD), necessitates a deeper understanding of its causes and treatments to enhance patient and caregiver quality of life.
- AD’s pathophysiology involves the buildup of amyloid-beta plaques and tau protein abnormalities, leading to neurotransmitter imbalances that affect brain function.
- FDA-approved treatments for AD can be divided into those addressing behavioral symptoms (like brexpiprazole for agitation) and cognitive decline (such as donepezil, a commonly prescribed cholinesterase inhibitor), each with specific mechanisms and side effects that require monitoring.
Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis.
Front Neurol
June 2023
Department of Neurology, Bishan Hospital of Chongqing Medical University, Chongqing, China.
Background: Non-ergot dopamine agonists (NEDAs) have been used as monotherapy or as an adjunctive therapy to levodopa for many years. Novel long-acting formulations of NEDAs including pramipexole extended-release (ER), ropinirole prolonged-release (PR), and rotigotine transdermal patch have been developed. However, there is no strong evidence that a given NEDA is more potent than another.
View Article and Find Full Text PDFEfficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta-analysis.
Eur J Neurol
March 2023
Department of Neurology, Bishan Hospital of Chongqing Medical University, Chongqing, China.
Background And Purpose: Non-ergot dopamine agonists (NEDAs) have been used as an adjunct therapy to levodopa in advanced Parkinson's disease (PD) for many years. However, there is no strong evidence that a given NEDA is more potent than another. To compare and rank the efficacy, tolerability, and safety of six commonly used NEDAs as an adjunct to levodopa in advanced PD, which includes long-acting and standard formulations, a network meta-analysis was performed.
View Article and Find Full Text PDFStimulants.
Child Adolesc Psychiatr Clin N Am
July 2022
Center for Psychiatry and Behavioral Medicine, Inc., 7351 Prairie Falcon Road, Suite 160, Las Vegas, NV 89128, USA. Electronic address:
Stimulants have been available for the treatment of attention-deficit/hyperactivity disorder (ADHD) for more than 70 years and are the most effective medications available. During the past 2 decades, several new immediate-release (IR) and extended-release methylphenidate (MPH) and amphetamine (AMPH) formulations have become available. These products differ by dose form (capsules, tablets, oral suspensions, oral disintegrating tablets, and patch), by onset and duration of effect, and by bioavailability.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!